- Fish farming group Benchmark said it expected to post full-year adjusted earnings growth of more than 65%.

Adjusted Ebitda for the year through September would be above £16.5m, as revenue grew by around 7% to above £150m, the company said in a trading statement.

In the advanced nutrition unit, earnings growth was driven by sales of specialist diets for shrimp, sea bass and sea bream, while earnings growth in the genetics unit was underpinned by investments in disease-resistant salmon eggs.

In health, the company said it achieved significant milestones towards the full commercial launch if its next generation sea lice treatment.

'2018 was a successful year for Benchmark with underlying earnings ahead of market expectations and delivery of strategic projects that will drive future growth and profitability,' the company said.

'Market conditions in our core salmon and shrimp markets remain favourable and the outlook is positive, with strong demographic and sustainability drivers, and an increasing trend towards professionalisation and consolidation amongst customers.'

'This, combined with an increasing recognition of the role that our innovative products can play in boosting yield, quality and sustainability, provides us with confidence in the future outlook.'

At 2:32pm: [LON:BMK] Benchmark Holdings Plc share price was 0p at 60.5p

Story provided by